12537 Once Daily Oral Atumelnant (CRN04894) Induces Rapid And Profound Reductions Of Androstenedione And 17-Hydroxyprogesterone In Participants With Classical Congenital Adrenal Hyperplasia: Initial Results From A 12-Week, Phase 2, Open-Label Study
Richard J. Auchus(University of Michigan), Umasuthan Srirangalingam(University College Hospital), Alejandro Ayala(Instituto Tecnológico de Morelia), Eduardo de la Torre(Crinetics Pharmaceuticals (United States)), Kathryn Jean Lucas(Lucas Research), Christine Ferrara-Cook(Crinetics Pharmaceuticals (United States)), Hjalmar Lagast(Amicus Therapeutics (United States)), Alan Krasner(Takeda (United States)), Stephen F. Betz(Abbott (United States)), Rosa Luo(Crinetics Pharmaceuticals (United States)), R. Scott Struthers(Crinetics Pharmaceuticals (United States)), Peter Trainer(University of Manchester), Darío Bruera(Misericordia University), Tânia A.S.S. Bachega(Universidade Federal de São Paulo), Yang Wu(Crinetics Pharmaceuticals (United States)), Jamie Marko(National Institutes of Health Clinical Center)
Cited by 8
Related Papers
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
|Cancer Cell|2017|791
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
|The Lancet|2001|643
Cytochrome b 5 Augments the 17,20-Lyase Activity of Human P450c17 without Direct Electron Transfer
|Journal of Biological Chemistry|1998|543